Art has over 40 years of experience as a pharmaceutical executive and life science venture capital investor. He founded Pappas Capital in 1994 and since then has raised over $540 million. Prior to Pappas Capital, Art held senior leadership positions at Glaxo Holdings, Abbott International, Merrell Dow Pharmaceuticals and the Dow Chemical Company.
Art is currently a director for Arix Bioscience, Aura Biosciences, OrphoMed and Reneo Pharmaceuticals, and a board observer for Amplyx Pharmaceuticals, Balance Therapeutics, and Real Endpoints. He also serves on several non-profit boards, including the North Carolina Biotechnology Center and The Wistar Institute. He is a decorated Vietnam veteran, having served in the US Army 101st Airborne Division. Art received a BS in Biology from The Ohio State University and an MBA in Finance from Xavier University.